|1.||Dehpour, Ahmad Reza: 17 articles (12/2014 - 06/2002)|
|2.||Fernández, Nuria: 13 articles (01/2014 - 08/2002)|
|3.||Monge, Luis: 13 articles (01/2014 - 08/2002)|
|4.||Diéguez, Godofredo: 13 articles (08/2012 - 08/2002)|
|5.||Pechánová, O: 11 articles (01/2009 - 01/2000)|
|6.||Shafaroodi, Hamed: 10 articles (07/2015 - 09/2004)|
|7.||Zicha, Josef: 10 articles (03/2014 - 03/2002)|
|8.||García-Villalón, Angel Luis: 10 articles (08/2012 - 08/2002)|
|9.||Simko, F: 9 articles (04/2013 - 02/2000)|
|10.||Simko, Fedor: 9 articles (09/2010 - 01/2004)|
|1.||Hypertension (High Blood Pressure)
08/01/2015 - "In rats with L-NAME induced hypertension there was a significant reduction of the blood pressure after two weeks treatment. "
05/01/2012 - "These results suggest that transient AT1 vaccination is as effective as continuous treatment with ARB, not only for the attenuation of hypertension, but also for the prevention of L-NAME-induced nephropathy in SHR."
12/01/2008 - "Solanum indicum ssp. distichum extract is effective against L-NAME-induced hypertension in rats."
05/01/2007 - "In conclusion, TQ is effective in protecting rats against l-NAME-induced hypertension and renal damage possibly via antioxidant activity."
10/09/2011 - "These results indicate that BA decreased blood pressure and improved ACh-induced endothelium-dependent vasorelaxation in L-NAME-induced hypertension rats, which may be mediated by reducing oxidative stress and retaining the bioavailability of NO in the cardiovascular system."
01/01/2010 - "In the second study, the late L-NAME group showed less blood flow recovery and smaller collateral artery diameter on day 28 of ischemia than the wild-type group. "
01/01/2010 - "In the second study, hind limb ischemia was induced in C57Bl/6 mice (wild-type) and C57Bl/6 mice treated with L-NAME from days 3 through 28 after induction of ischemia. "
01/01/2006 - "The present study reveals that L-NAME protects against I/R injury when the inhibitor is administered 24 hrs before ischemia. "
07/01/1995 - "Therefore, additional studies were performed in rats instrumented for cardiovascular studies to evaluate the acute hemodynamic responses during the first 90 min of reperfusion following renal ischemia in rats pretreated with L-NAME. "
02/04/2011 - "Pre-treatment with l-NAME, l-NIL and 7-NI significantly reduced the infarct volume and prevented ischemia-induced reduction in IkB-alpha expression. "
03/10/2000 - "Since these phenomena have usually been described with high (or moderate) doses of L-NAME, this study was undertaken to evaluate the effects of a low dose of L-NAME on arterial blood pressure, heart weight index, left ventricular weight index, amount of ventricular fibrosis, and cardiomyocyte size. "
10/01/1999 - "Pathohistological study demonstrated increased pericardiac fibrosis and coronary arterial injury score in the L-NAME group in a dose-dependent manner. "
11/19/2013 - "Additionally, TM5441-treated mice had a 34% reduction in periaortic fibrosis relative to animals on L-NAME alone. "
11/01/2013 - "L-NAME and eNOS(-/-) markedly increased the fibrosis induced by TAC and enhanced the myocardial prevalence of CXCR4(pos) fibroblasts. "
11/01/2013 - "Inhibition of eNOS by L-NAME induced interstitial fibrosis, augmented replacement fibrosis, and induced apoptosis of cardiac fibroblasts and cardiomyocytes. "
05/14/2014 - "Varying degrees of proteinuria were seen and arterial blood pressure increased in l-NAME-treated pregnant rats (p<0.01). "
07/01/2013 - "Elevated blood pressure, proteinuria, and intrauterine growth restriction associated with PE were induced in Sprague-Dawley rats using L-NAME. "
05/01/2012 - "Vaccination against the AT1 receptor caused a significant increase in AT1 receptor titers, and a sustained decrease in BP. L-NAME treatment resulted in a marked increase in proteinuria in the control groups, which was completely suppressed in the AT1 vaccine-treated group, and glomerular injury scores were also significantly decreased. "
01/01/2012 - "L-NAME treatment in pregnant rats caused significant SBP elevation and severe proteinuria. "
01/01/2011 - "L-NAME reproduces a preeclamptic-like condition with increased blood pressure, proteinuria, growth restriction and intrauterine mortality. "
06/01/1999 - "Our study also demonstrated that pretreatment with L-NAME reduced the seizure activity and neuronal cell death in the hippocampus elicited by the systemic administration of KA in the neonatal brain. "
12/01/2014 - "Interestingly, such seizures and mortality in rats were antagonized by L-NAME and 7-NI pretreatments. "
01/01/2013 - "An administration of L-NAME or ODQ delayed the onset of initial seizure, increased latency till death, and produced a 25% survival rate. "
06/01/2012 - "These effects and changed biochemical parameters in the brains of animals treated by L-NAME before MB in comparison to MB-treated group suggest involvement of NO in MB's effects in the animal model of PTZ-evoked convulsions."
03/04/2011 - "Pre-treatment with L-NAME prevented this trend of increase in CBF whereas the injection of 7NI even decreased CBF between seizures. "
|1.||NG-Nitroarginine Methyl Ester (L-NAME)
|2.||Nitric Oxide Synthase (NO Synthase)
|4.||Nitric Oxide (Nitrogen Monoxide)
|5.||arginine methyl ester
|7.||omega-N-Methylarginine (NG Monomethyl L Arginine)